CHCéline Hervieu

Céline Hervieu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Céline Hervieu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Etude comparative des cellules souches cancéreuses issues de tumeurs primitives et de métastases de cancer colorectal

    by Celine Hervieu

    Le cancer colorectal (CCR) est l’une des principales causes de décès par cancer dans le monde. L’évolution d’un stade localisé en un stade métastatique est particulièrement critique pour la survie des patients. Cette transition est souvent associée au développement de résistances thérapeutiques, attribuées aux cellules souches cancéreuses (CSC), à l’origine des récidives et de la survenue de métastases. Ainsi, les CSC représentent une cible thérapeutique prometteuse. L’étude de ces cellules nécessite leur identification et leur isolement, qui constituent un réel défi en raison de leur faible proportion au sein de la tumeur et de leur nature dynamique. Mes travaux de thèse ont porté sur l’étude comparative des CSC issues de tumeurs primaires et de métastases de CCR, en terme de caractéristiques et de réponse aux chimiothérapies. La plasticité des CSC, notamment phénotypique, complique leur isolement via des marqueurs de surface. Dans ce projet, nous avons utilisé la technique de fractionnement par couplage flux-force de sédimentation pour trier les cellules en fonction de leurs propriétés biophysiques. Trois sous-populations cellulaires ont été isolées à partir de lignées cellulaires et de cultures primaires, représentatives des différents stades de CCR. Les caractérisations phénotypiques et fonctionnelles des sous-populations triées ont révélé que l’une d’entre elles possède des propriétés de CSC, en particulier une quiescence, une clonogénicité et une capacité à générer des tumeurs in vivo. De plus, les tests de sensibilité ont mis en évidence le caractère chimiorésistant de cette sous-population. Ainsi, cette approche « label-free » permet d’étudier l’impact de l’hétérogénéité cellulaire intratumorale et des CSC sur les réponses aux chimiothérapies, utilisées en clinique, quel que soit la matrice cellulaire et le stade tumoral. Ces travaux ouvrent donc de nouvelles perspectives pour étudier la réponse individualisée de chaque compartiment cellulaire tumoral et les résistances thérapeutiques. In fine, ce projet pourrait permettre la personnalisation des thérapies systémiques, afin d’optimiser leur efficacité et prévenir les récidives.

  • Open Access

    Ultra-High-Frequency-Dielectrophoresis Microfluidic Biosensor to Detect the Transformation Potential of Extracellular Vesicles Derived from Cancer Stem Cells

    by Elodie Barthout, Elisa Lambert, Stéphanie Durand, Céline Hervieu, Léa Ikhlef, Sofiane Saada, Rémi Manczak, Julie Pannequin, Arnaud Pothier, Claire Dalmay, et al.

    Cancer stem cells (CSCs) remain challenging to isolate and characterize because of their plastic phenotype. To overcome this issue, we used a microfluidic lab-on-a-chip analysis approach based on ultra-high frequency dielectophoresis (UHF-DEP) to measure the dielectrophoretic signature of colorectal cancer cells. We demonstrated that CSCs exhibit a distinct and lower frequency signature than differentiated cancer cells. Extracellular vesicles (EVs) released by tumor cells are implicated in tumor progression and metastasis. As CSC-derived EVs carry a more aggressive cargo, we hypothesized that treating differentiated colorectal cancer cells with these vesicles might affect their phenotype which would be detected by our lab on a chip. Indeed, the dielectrophoretic signature of cells treated with those EVs was altered in comparison to untreated cells, even in cases where no detectable biological changes were observed. Compared to conventional approaches using biomarkers to characterize CSCs, this UHF-DEP lab on a chip is a label-free method providing rapid and relevant results. Such a method could be useful in the clinic for the early detection of CSCs in the tumor mass, as well as for monitoring CSC-derived EVs in the bloodstream in order to study responses to therapy and prevent relapses.


  • Open Access

    UHF-Dielectrophoresis Microfluidic Lab-on-a-Chip to Detect the Transformation Potential of Extracellular Vesicles Derived From Cancer Stem Cells

    by Élodie Barthout, Élisa Lambert, Céline Hervieu, Sofiane Saada, Rémi Manczak, Julie Pannequin, Arnaud Pothier, Claire Dalmay, Fabrice Lalloué, Muriel Mathonnet, et al.

    C ancer stem cells remain a challenge to isolate and characterize because of their plastic phenotype. Using a microfluidic lab-on-a-chip based on ultra-high frequency dielectophoresis, we measured the electromagnetic signature of colorectal cancer cells and demonstrated that cancer stem cells show a distinct and lower electromagnetic signature than differentiated cells. The release of extracellular vesicles from tumor cells can drive tumor progression and metastasis development. As extracellular vesicles from cancer stem cells carry more aggressive content, we treated colorectal cancer cells with these vesicles to test whether the lab-on-a-chip can detect a change in phenotype. The electromagnetic signature of treated cells is modified in comparison to untreated cells and sometimes even when no biological change is observed. The lab-on-a-chip provides rapid and relevant result without prior labeling compared to conventional biological approaches. It could be useful in the clinic for early detection of cancer stem cells in the tumor mass and for monitoring the aggressive potential of extracellular vesicles in the bloodstream in order to adapt therapeutic management and prevent relapse.


  • Open Access

    A Label-Free Cell Sorting Approach to Highlight the Impact of Intratumoral Cellular Heterogeneity and Cancer Stem Cells on Response to Therapies

    by Céline Hervieu, Mireille Verdier, Elodie Barthout, Gaëlle Bégaud, Niki Christou, Magali Sage, Julie Pannequin, Serge Battu, Muriel Mathonnet

    Cancer stem cells play a crucial role in tumor initiation, metastasis, and resistance to treatment. Cellular heterogeneity and plasticity complicate the isolation of cancer stem cells. The impact of intra-tumor cellular heterogeneity using a label-free approach remains understudied in the context of treatment resistance. Here, we use the sedimentation field–flow fractionation technique to separate, without labeling, cell subpopulations of colorectal cancer cell lines and primary cultures according to their biophysical properties. One of the three sorted cell subpopulations exhibits characteristics of cancer stem cells, including high tumorigenicity in vivo and a higher frequency of tumor-initiating cells compared to the other subpopulations. Due to its chemoresistance, two- and three-dimensional in vitro chemosensitivity assays highlight the therapeutic relevance of this cancer stem cell subpopulation. Thus, our results reveal the major implication of intra-tumor cellular heterogeneity, including cancer stem cells in treatment resistance, thanks to our label-free cell sorting approach. This approach enables—by breaking down the tumor—the study the individualized response of each sorted tumor cell subpopulation and to identify chemoresistance, thus offering new perspectives for personalized therapy.


  • Open Access

    A Label-Free Cell Sorting Approach to Highlight the Impact of Intratumoral Cellular Heterogeneity and Cancer Stem Cells on Response to Therapies

    by Céline Hervieu, Mireille Verdier, Gaëlle Bégaud, Niki Christou, Magali Sage, Julie Pannequin, Serge Battu, Muriel Mathonnet

    Cancer stem cells play a crucial role in tumor initiation, metastasis and therapy resistance. Cellular heterogeneity and plasticity challenge the isolation of cancer stem cells. The impact of intratumoral cellular heterogeneity in the context of treatment resistance using a label-free approach remains understudied. Here, we use the sedimentation field-flow fractionation technique to separate, without labeling, cell subpopulations of colorectal cancer cell lines and primary cultures according to their biophysical properties. One of the three cell subpopulations sorted by SdFFF exhibits cancer stem cell traits, including high tumorigenicity in vivo, and a higher frequency of tumor-initiating cells compared to the other subpopulations. In vitro two- and three-dimensional chemosensitivity assays emphasize the therapeutic relevance of this cancer stem cell-like subpopulation due to its chemoresistance. Therefore, our findings highlight a label-free cell sorting approach to reveal intratumoral cellular heterogeneity and its implication in therapy resistance. This approach enables the study of the individualized response of each sorted cell subpopulation by breaking down the tumor, thus offering new perspectives for personalized therapy.


  • Open Access

    Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives

    by Niki Christou, Clément Auger, Serge Battu, Fabrice Lalloué, Marie-Odile Jauberteau-Marchan, Céline Hervieu, Mireille Verdier, Muriel Mathonnet

    (1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers—in particular, digestive (stomach, pancreas, colorectal, appendix) and gynecological (ovaries) ones in the form of metastases. The aim of the treatment is a maximal reduction of the macroscopic disease called “cytoreduction” in combination with hyperthermic intra-abdominal chemotherapy to treat residual microscopic lesions. (2) Methods: In this narrative review, we fundamentally synthetize the evolution of this process over time and its impact on clinical applications. (3) Results: Over the last past decade, different evolutions concerning both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have been realized. (4) Conclusion: The final objective of these evolutions is the improvement of the global and recurrence-free survival of primary and secondary malignant peritoneal pathologies. However, more large randomized controlled trials are needed to demonstrate the efficacy of such treatments with the help of molecular biology and genetics.


  • Open Access

    The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials

    by Céline Hervieu, Niki Christou, Serge Battu, Muriel Mathonnet

    The treatment options available for colorectal cancer (CRC) have increased over the years and have significantly improved the overall survival of CRC patients. However, the response rate for CRC patients with metastatic disease remains low and decreases with subsequent lines of therapy. The clinical management of patients with metastatic CRC (mCRC) presents a unique challenge in balancing the benefits and harms while considering disease progression, treatment-related toxicities, drug resistance and the patient’s overall quality of life. Despite the initial success of therapy, the development of drug resistance can lead to therapy failure and relapse in cancer patients, which can be attributed to the cancer stem cells (CSCs). Thus, colorectal CSCs (CCSCs) contribute to therapy resistance but also to tumor initiation and metastasis development, making them attractive potential targets for the treatment of CRC. This review presents the available CCSC isolation methods, the clinical relevance of these CCSCs, the mechanisms of drug resistance associated with CCSCs and the ongoing clinical trials targeting these CCSCs. Novel therapeutic strategies are needed to effectively eradicate both tumor growth and metastasis, while taking into account the tumor microenvironment (TME) which plays a key role in tumor cell plasticity.


  • Open Access

    Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

    by Vincent Faugeroux, Emma Pailler, Marianne Oulhen, Olivier Deas, Laura Brulle-Soumare, Céline Hervieu, Virginie Marty, Kamelia Alexandrova, Kiki C. Andree, Nikolas H. Stoecklein, et al.

    Transformation of castration-resistant prostate cancer (CRPC) into an aggressive neuroendocrine disease (CRPC-NE) represents a major clinical challenge and experimental models are lacking. A CTC-derived eXplant (CDX) and a CDX-derived cell line are established using circulating tumor cells (CTCs) obtained by diagnostic leukapheresis from a CRPC patient resistant to enzalutamide. The CDX and the derived-cell line conserve 16% of primary tumor (PT) and 56% of CTC mutations, as well as 83% of PT copy-number aberrations including clonal TMPRSS2-ERG fusion and NKX3.1 loss. Both harbor an androgen receptor-null neuroendocrine phenotype, TP53, PTEN and RB1 loss. While PTEN and RB1 loss are acquired in CTCs, evolutionary analysis suggest that a PT subclone harboring TP53 loss is the driver of the metastatic event leading to the CDX. This CDX model provides insights on the sequential acquisition of key drivers of neuroendocrine transdifferentiation and offers a unique tool for effective drug screening in CRPC-NE management.